Quinidine Revisited

American Journal of Medicine

Volumn 122, Issue 4, 2009, Pages 317-321

  Yang, Felix ^a   Hanon, Sam ^a   Lam, Patrick ^a   Schweitzer, Paul ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Antiarrhythmic drug therapy; Arrhythmia; Atrial fibrillation; Brugada syndrome; Idiopathic ventricular fibrillation; Quinidine; Short QT syndrome

Indexed keywords

AMIODARONE; DILTIAZEM; FLECAINIDE; HYDROXYQUINIDINE; IBUTILIDE; METOPROLOL; MEXILETINE; NIFEDIPINE; PROPAFENONE; PROPRANOLOL; QUINIDINE; QUINIDINE DERIVATIVE; SOTALOL; TOCAINIDE; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

ACTION POTENTIAL; BRUGADA SYNDROME; CARDIOVERSION; DEFIBRILLATOR; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG USE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SHORT QT SYNDROME; SINUS RHYTHM; SUDDEN DEATH; SYNCOPE; TACHYCARDIA; TORSADE DES POINTES;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; HEART DISEASES; HUMANS; QUINIDINE; VENTRICULAR FIBRILLATION;

EID: 63049118250     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.11.019     Document Type: Review

References (43)

1. Halinen M.O., Huttunen M., Paakkinen S., and Tarssanen L. Comparison of sotalol with digoxin-quinidine for conversion of acute atrial fibrillation to sinus rhythm (the Sotalol-Digoxin-Quinidine Trial). Am J Cardiol 76 (1995) 495-498
2. Miller M.R., McNamara R.L., Segal J.B., et al. Efficacy of agents for pharmacologic conversion of atrial fibrillation and subsequent maintenance of sinus rhythm: a meta-analysis of clinical trials. J Fam Pract 49 (2000) 1033-1046
3. Innes G.D., Vertesi L., Dillon E.C., and Metcalfe C. Effectiveness of verapamil-quinidine versus digoxin-quinidine in the emergency department treatment of paroxysmal atrial fibrillation. Ann Emerg Med 29 (1997) 126-134
4. Nichol G., McAlister F., Pham B., et al. Meta-analysis of randomised controlled trials of the effectiveness of antiarrhythmic agents at promoting sinus rhythm in patients with atrial fibrillation. Heart 87 (2002) 535-543
5. Selzer A., and Wray H.W. Quinidine syncope. paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30 (1964) 17-26
6. Coplen S.E., Antman E.M., Berlin J.A., et al. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 82 (1990) 1106-1116
7. Southworth M.R., Zarembski D., Viana M., and Bauman J. Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation. Am J Cardiol 83 (1999) 1629-1632
8. Lafuente-Lafuente C., Mouly S., Longas-Tejero M.A., and Bergmann J.F. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 4 (2007) CD005049
9. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 321 (1989) 406-412
10. Moosvi A.R., Goldstein S., VanderBrug Medendorp S., et al. Effect of empiric antiarrhythmic therapy in resuscitated out-of-hospital cardiac arrest victims with coronary artery disease. Am J Cardiol 65 (1990) 1192-1197
11. Morganroth J., and Goin J.E. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. A meta-analysis. Circulation 84 (1991) 1977-1983
12. Fang M.C., Stafford R.S., Ruskin J.N., and Singer D.E. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med 164 (2004) 55-60
13. Takanaka C., and Singh B.N. Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarizations: significance of slow channel activity and differing effects of quinidine and amiodarone. J Am Coll Cardiol 15 (1990) 213-221
14. Zhou J.T., Zheng L.R., and Liu W.Y. Role of early afterdepolarization in familial long QTU syndrome and torsades de pointes. Pacing Clin Electrophysiol 15 11 Pt 2 (1992) 2164-2168
15. Shimizu W., Ohe T., Kurita T., et al. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol 26 (1995) 1299-1309
16. Liao W.B., Bullard M.J., Kuo C.T., et al. Anticholinergic overdose induced torsades de pointes successfully treated with verapamil. Jpn Heart J 37 (1996) 925-931
17. de Paola A.A., and Veloso H.H. Efficacy and safety of sotalol versus quinidine for the maintenance of sinus rhythm after conversion of atrial fibrillation. SOCESP Investigators. The Cardiology Society of Sao Paulo. Am J Cardiol 84 (1999) 1033-1037
18. Juul-Moller S., Edvardsson N., and Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 82 (1990) 1932-1939
19. Fetsch T., Bauer P., Engberding R., et al. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J 25 (2004) 1385-1394
20. Patten M., Maas R., Bauer P., et al. Suppression of paroxysmal atrial tachyarrhythmias--results of the SOPAT trial. Eur Heart J 25 (2004) 1395-1404
21. Patten M., Maas R., Karim A., et al. Event-recorder monitoring in the diagnosis of atrial fibrillation in symptomatic patients: subanalysis of the SOPAT trial. J Cardiovasc Electrophysiol 17 (2006) 1216-1220
22. Leahey Jr. E.B., Reiffel J.A., Drusin R.E., et al. Interaction between quinidine and digoxin. JAMA 240 (1978) 533-534
23. Ometto R., Arfiero S., and Vincenzi M. [Torsades de pointes induced by quinidine: a case treated successfully with verapamil]. G Ital Cardiol 20 (1990) 431-434
24. Lafuente-Lafuente C., Mouly S., Longas-Tejero M.A., et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med 166 (2006) 719-728
25. Crijns H.J., Wiesfeld A.C., Posma J.L., and Lie K.I. Favourable outcome in idiopathic ventricular fibrillation with treatment aimed at prevention of high sympathetic tone and suppression of inducible arrhythmias. Br Heart J 74 (1995) 408-412
26. Priori S.G., Paganini V., Boccalatte L., and Schwartz P.J. [Idiopathic ventricular fibrillation: from a collection of clinical cases to a prospective evaluation. The U-CARE Steering Committee. Unexplained Cardiac Arrest Registry of Europe]. G Ital Cardiol 25 (1995) 149-158
27. Belhassen B., Viskin S., Fish R., et al. Effects of electrophysiologic-guided therapy with class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol 10 (1999) 1301-1312
28. Brugada P., and Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 20 (1992) 1391-1396
29. Antzelevitch C., Brugada P., Borggrefe M., et al. Brugada syndrome: report of the second consensus conference: endorsed by the Heart Rhythm Society and the European Heart Rhythm Association. Circulation 111 (2005) 659-670
30. Imaizumi Y., and Giles W.R. Quinidine-induced inhibition of transient outward current in cardiac muscle. Am J Physiol 253 3 Pt 2 (1987) H704-H708
31. Antzelevitch C. The Brugada syndrome: ionic basis and arrhythmia mechanisms. J Cardiovasc Electrophysiol 12 (2001) 268-272
32. Gussak I., Antzelevitch C., Bjerregaard P., et al. The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol 33 (1999) 5-15
33. Antzelevitch C., Yan G., Shimizu W., and Burashnikov A. Electrical heterogeneity, the ECG, and cardiac arrhythmias. In: Zipes D., and Jalife J. (Eds). Cardiac Electrophysiology: From Cell to Bedside (2000), WB Saunders Co, Philadelphia 890-903
34. Yan G.X., and Antzelevitch C. Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation 100 (1999) 1660-1666
35. Belhassen B., Glick A., and Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation 110 (2004) 1731-1737
36. Mok N.S., Chan N.Y., and Chiu A.C. Successful use of quinidine in treatment of electrical storm in Brugada syndrome. Pacing Clin Electrophysiol 27 6 Pt 1 (2004) 821-823
37. Marquez M.F., Rivera J., Hermosillo A.G., et al. Arrhythmic storm responsive to quinidine in a patient with Brugada syndrome and vasovagal syncope. Pacing Clin Electrophysiol 28 (2005) 870-873
38. Haghjoo M., Arya A., Heidari A., and Sadr-Ameli M.A. Suppression of electrical storm by oral quinidine in a patient with Brugada syndrome. J Cardiovasc Electrophysiol 16 (2005) 674
39. Hermida J.S., Denjoy I., Clerc J., et al. Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol 43 (2004) 1853-1860
40. Mizusawa Y., Sakurada H., Nishizaki M., and Hiraoka M. Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: low-dose quinidine therapy as an adjunctive treatment. J Cardiovasc Pharmacol 47 (2006) 359-364
41. Gaita F., Giustetto C., Bianchi F., et al. Short QT syndrome: pharmacological treatment. J Am Coll Cardiol 43 (2004) 1494-1499
42. Gussak I., Chaitman B.R., Kopecky S.L., and Nerbonne J.M. Rapid ventricular repolarization in rodents: electrocardiographic manifestations, molecular mechanisms, and clinical insights. J Electrocardiol 33 (2000) 159-170
43. Wolpert C., Schimpf R., Giustetto C., et al. Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol 16 (2005) 54-58